NEW YORK – Wall Street analysts took a mixed view of Myriad Genetics today following the announcement on Friday by the US Supreme Court that it would review a lawsuit challenging the company’s patents related to the BRCA1 and BRCA2 genes.
View the original article here: Analysts Provide Mixed Views on Myriad After Supreme Court Agrees to Rehear Patent Case
 |
Infographics | More... |
Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar? 
Embryos aren’t female by ‘default’ after all, study shows 
Why you may soon be shopping for tomatoes enhanced with snapdragon flower genes 
Viewpoint: Should you be concerned when you read that a chemical in your food has been linked to cancer? Here’s an epidemiologist’s checklist to detect over-hyped scares 
Marrying your cousin? There may be evolutionary benefits 
Many animals can walk at birth. Why are human babies born with so few skills? 
Why humans have larger penises and smaller testicles than other great apes 
How common is incest? Rise of genetic testing reveals disturbing evidence 
Viewpoint: By engineering block on Vitamin A enhanced Golden Rice, Greenpeace ‘puts the whole environmental movement into disrepute’ 
Viewpoint: The organic food industry is a $180 billion marketing fraud 
